Meeting
2024 ASCO Annual Meeting
The clinical utility of a circulating tumor cell based cerebrospinal fluid assay in the diagnosis and molecular analysis of leptomeningeal disease in patients with metastatic non-small cell lung cancer.
Authors
Ramya Muddasani
Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA
Ramya Muddasani , Amanda Reyes , Jeremy Fricke , Isa Mambetsariev , Erminia Massarelli , Michelle Afkhami , Ravi Salgia , Jyoti Malhotra
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8644)
DOI
10.1200/JCO.2024.42.16_suppl.8644
Abstract #
8644
Poster Bd #
508
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase Ia/Ib study of intrathecal deferoxamine in patients with leptomeningeal metastases.
First Author: Jessica Wilcox
Poster
2017 ASCO Annual Meeting
Evaluation of liquid biopsies for molecular profiling in untreated patients with stage III/IV non-small cell lung cancer (NSCLC).
First Author: Benjamin Besse
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The expanded indications of HER2-targeted therapies by monitoring of circulating tumor cells.
First Author: Yasuaki Kimura
Poster
2023 ASCO Breakthrough
Personalized medicine for brain metastases (BrMets) through patient-derived organoid (PDO) drug testing.
First Author: Aki Morikawa